Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Liabilities and Shareholders Equity (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $63.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 37.8% year-over-year to $63.8 million, compared with a TTM value of $315.1 million through Sep 2025, down 36.52%, and an annual FY2024 reading of $92.2 million, down 36.01% over the prior year.
  • Liabilities and Shareholders Equity was $63.8 million for Q3 2025 at Ovid Therapeutics, down from $77.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $237.5 million in Q1 2021 and bottomed at $63.8 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $145.4 million, with a median of $143.4 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity soared 380.65% in 2021, then crashed 37.96% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $194.5 million in 2021, then fell by 20.19% to $155.3 million in 2022, then dropped by 7.24% to $144.0 million in 2023, then plummeted by 36.01% to $92.2 million in 2024, then plummeted by 30.73% to $63.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for OVID at $63.8 million in Q3 2025, $77.4 million in Q2 2025, and $81.7 million in Q1 2025.